File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nur77: A potential therapeutic target in cancer

TitleNur77: A potential therapeutic target in cancer
Authors
Keywordscancer
genomic
non-genomic
Nur77
targeted therapy
Issue Date2012
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
Citation
Expert Opinion On Therapeutic Targets, 2012, v. 16 n. 6, p. 573-585 How to Cite?
AbstractThe orphan nuclear receptor Nur77 (also known as NR4A1, NGFIB, TR3, TIS1, NAK-1, or N10) is a unique transcription factor encoded by an immediate early gene. Nur77 signaling is deregulated in many cancers and constitutes an important molecule for drug targeting. Areas covered: Nur77 as a versatile transcription factor that displays distinct dual roles in cell proliferation and apoptosis. In addition, several recent insights into Nur77's non-genomic signaling through its physical interactions with various signaling proteins and its phosphorylation-dependent regulation will be highlighted. The possible mechanisms by which Nur77 supports carcinogenesis and specific examples in different human cancers will be summarized. Different approaches to target Nur77 using mimetics, natural products, and synthetic compounds are also described. Expert opinion: These latest findings shed light on the novel roles of Nur77 as an exploitable target for new cancer therapeutics. Further work which focuses on a more complete understanding of the Nur77 interactome as well as how the different networks of Nur77 functional interactions are orchestrated in a stimulus or context-specific way will aid the development of more selective, non-toxic approaches for targeting Nur77 in future. © 2012 Informa UK, Ltd.
DescriptionReview
Persistent Identifierhttp://hdl.handle.net/10722/160577
ISSN
2015 Impact Factor: 4.798
2015 SCImago Journal Rankings: 2.025
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTo, SKYen_HK
dc.contributor.authorZeng, JZen_HK
dc.contributor.authorWong, ASTen_HK
dc.date.accessioned2012-08-16T06:14:45Z-
dc.date.available2012-08-16T06:14:45Z-
dc.date.issued2012en_HK
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2012, v. 16 n. 6, p. 573-585en_HK
dc.identifier.issn1472-8222en_HK
dc.identifier.urihttp://hdl.handle.net/10722/160577-
dc.descriptionReview-
dc.description.abstractThe orphan nuclear receptor Nur77 (also known as NR4A1, NGFIB, TR3, TIS1, NAK-1, or N10) is a unique transcription factor encoded by an immediate early gene. Nur77 signaling is deregulated in many cancers and constitutes an important molecule for drug targeting. Areas covered: Nur77 as a versatile transcription factor that displays distinct dual roles in cell proliferation and apoptosis. In addition, several recent insights into Nur77's non-genomic signaling through its physical interactions with various signaling proteins and its phosphorylation-dependent regulation will be highlighted. The possible mechanisms by which Nur77 supports carcinogenesis and specific examples in different human cancers will be summarized. Different approaches to target Nur77 using mimetics, natural products, and synthetic compounds are also described. Expert opinion: These latest findings shed light on the novel roles of Nur77 as an exploitable target for new cancer therapeutics. Further work which focuses on a more complete understanding of the Nur77 interactome as well as how the different networks of Nur77 functional interactions are orchestrated in a stimulus or context-specific way will aid the development of more selective, non-toxic approaches for targeting Nur77 in future. © 2012 Informa UK, Ltd.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/etten_HK
dc.relation.ispartofExpert Opinion on Therapeutic Targetsen_HK
dc.rightsExpert Opinion on Therapeutic Targets. Copyright © Informa Healthcare.-
dc.subjectcanceren_HK
dc.subjectgenomicen_HK
dc.subjectnon-genomicen_HK
dc.subjectNur77en_HK
dc.subjecttargeted therapyen_HK
dc.subject.meshAnimals-
dc.subject.meshCell Differentiation-
dc.subject.meshNeoplasms - metabolism-
dc.subject.meshNuclear Receptor Subfamily 4, Group A, Member 1 - metabolism-
dc.subject.meshStem Cells - cytology-
dc.titleNur77: A potential therapeutic target in canceren_HK
dc.typeArticleen_HK
dc.identifier.emailWong, AST: awong1@hkucc.hku.hken_HK
dc.identifier.authorityWong, AST=rp00805en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14728222.2012.680958en_HK
dc.identifier.pmid22537097-
dc.identifier.scopuseid_2-s2.0-84861325157en_HK
dc.identifier.hkuros203399en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84861325157&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue6en_HK
dc.identifier.spage573en_HK
dc.identifier.epage585en_HK
dc.identifier.isiWOS:000304091400004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTo, SKY=55224317600en_HK
dc.identifier.scopusauthoridZeng, JZ=7402652375en_HK
dc.identifier.scopusauthoridWong, AST=23987963300en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats